ReviewNanomaterials (Basel, Switzerland)2025
Combating Healthcare-Associated Infections in Modern Hospitals: Nanotechnology-Based Approaches in the Era of Antimicrobial Resistance.
Review in Nanomaterials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- National surveillance of antimicrobial resistance in Iran using IAMR software: A hospital-based study.New microbes and new infections · 2026Article
- Silver Nanoparticle-Functionalized Medical Devices for Primary Prevention of Healthcare-Associated Infections: In Vitro Efficacy Against Multidrug-Resistant Clinical Isolates.Microorganisms · 2026Article
- Environmental Application of Newly Designed Loop-Mediated Isothermal Amplification (LAMP) Kits for Nosocomial Pathogen Detection in Hospital Settings.Life (Basel, Switzerland) · 2026Article
- Biogenic Selenium Nanoparticles Functionalized with Natural Polymers or Phytochemicals for Targeted Disruption ofJournal of functional biomaterials · 2026Review
- Engineering Mesoporous Silica Hosts for Ultrasmall ZnO Nanoparticles: A Dendritic Polymer-Assisted Strategy Towards Sustainable, Safe, and Effective Antibacterial Systems.Nanomaterials (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Healthcare-associated infections (HAIs) represent one of the most persistent challenges in modern healthcare delivery, affecting millions of patients worldwide and imposing substantial clinical and economic burdens on healthcare systems. The emergence of antimicrobial resistance (AMR) has further complicated infection management, creating an urgent need for innovative therapeutic and preventive strategies. Current strategies for combating AMR in hospital settings encompass comprehensive infection prevention and control measures, antimicrobial stewardship programs, enhanced environmental cleaning protocols and innovative surface modification technologies. Nanotechnology has emerged as a valuable approach to address the limitations of conventional antimicrobial strategies. Various nanomaterial categories offer innovative platforms for developing novel treatment strategies and for providing advantages including reduced toxicity through lower dosage requirements, diminished resistance development potential, and enhanced antibacterial effects through combined action mechanisms. Particularly, metal-based nanoparticles and their oxides demonstrate exceptional antimicrobial properties through multiple mechanisms including membrane damage, protein binding and reactive oxygen species generation. This comprehensive review examines the current landscape of hospital-acquired infections, the growing threat of antimicrobial resistance, and the promising role of nanotechnology-based solutions, with particular emphasis on silver nanoparticles as innovative tool for HAI control in clinical settings. Recent advances in nanotechnology-enabled antimicrobial coatings are assessed along with their clinical translation in hospital settings, identifying key barriers concerning material durability, safety profiles, and regulatory pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.